stockportfolio.pro
Bio-Techne Corporation (TECH)
Healthcare · Biotechnology · NasdaqGS
Bio-Techne Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $499.02M | $563.00M | $642.99M | $714.01M | $738.69M | $931.03M | $1.11B | $1.14B | $1.16B | $1.22B |
| Gross profit | $336.66M | $374.54M | $432.14M | $473.49M | $483.19M | $632.85M | $756.50M | $769.82M | $769.73M | $790.27M |
| Net income | $104.48M | $76.09M | $126.15M | $96.07M | $229.30M | $140.41M | $272.05M | $285.26M | $168.10M | $73.40M |
| Net margin | 20.9% | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
Source: Bio-Techne Corporation SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into TECH stock?
At today's market cap of $8.52B, Bio-Techne Corporation is priced for free-cash-flow growth of about 14.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $256.55M from the FY ending 2025-06-30). For comparison, free cash flow actually grew 10.8%/yr over the last five fiscal years and revenue 10.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Bio-Techne Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TECH in your portfolio →
Bio-Techne Corporation financial history by metric
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation — frequently asked questions
What is Bio-Techne Corporation's revenue?
Bio-Techne Corporation (TECH) reported revenue of $1.22B for fiscal year 2025, up 5.2% from the prior year, according to its SEC filings.
Is Bio-Techne Corporation profitable?
Yes. TECH earned net income of $73.40M in fiscal 2025, a net margin of 6.0%.
What is TECH's P/E ratio?
Bio-Techne Corporation trades at a price-to-earnings ratio of about 77.7 based on the latest data in our nightly-refreshed cache.
How fast is Bio-Techne Corporation growing?
TECH's revenue grew at roughly 10.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bio-Techne Corporation have?
As of fiscal year 2025, TECH carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bio-Techne Corporation's gross margin?
TECH's gross margin was 64.8% in fiscal 2025 — gross profit of $790.27M on revenue of $1.22B.
What is Bio-Techne Corporation's market cap?
Bio-Techne Corporation (TECH) has a market capitalization of about $8.52B, based on the latest data in our nightly-refreshed cache.
When does Bio-Techne Corporation's fiscal year end?
TECH's fiscal year ends in June. Its most recent annual filing covers the fiscal year ending 2025-06-30.
What growth is priced into TECH stock?
At today's market cap of $8.52B, Bio-Techne Corporation is priced for free-cash-flow growth of about 14.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $256.55M from the FY ending 2025-06-30). For comparison, free cash flow actually grew 10.8%/yr over the last five fiscal years and revenue 10.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Bio-Techne Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.